Investment highlights

Sosei Heptares is a clinical-stage company focused on discovering, designing and developing innovative medicines in areas of high unmet medical need.

Our R&D pipeline of novel partnered, and in-house drug candidates target a wide range of diseases and therapeutic areas including neurology, immuno-oncology, gastroenterology, inflammation and rare/specialty diseases.

We leverage our proprietary StaR® technology and proven SBDD platform in the discovery and design of our new drug candidates.

 

Why invest in us?

  • Our track record of successful approved medicines which underpin strong and stable royalty streams to support our research and development

  • Our dedicated scientists, clinicians and employees whose ideas and research are regularly published in the most prestigious academic journals globally

  • Our proprietary StaR® technology fuels our discovery efforts and has created multiple clinical candidates; furthermore, world-leading pharmaceutical companies have extensively sought to license the technology for their own programs

  • Our SBDD platform continually refills our pipeline with high-value drug candidates

  • Our diversified in-house and partnered pipeline of 15 discovery, 5 preclinical and 6 clinical development candidates across therapeutic areas including neurology, immuno-oncology, gastroenterology, inflammation and other rare/specialty diseases

  • Our flexible business model combines in-house development, multiple existing and new partnerships and joint ventures

  • Our robust IP estate of over 40+ patent families, 200+ issued patents and 200+ patent applications

  • Our management team with over 150 years’ combined industry experience across the global pharma and biotech landscape